608 related articles for article (PubMed ID: 11317659)
1. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51).
Clarke P; Gray A; Adler A; Stevens R; Raikou M; Cull C; Stratton I; Holman R;
Diabetologia; 2001 Mar; 44(3):298-304. PubMed ID: 11317659
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72).
Clarke PM; Gray AM; Briggs A; Stevens RJ; Matthews DR; Holman RR;
Diabetologia; 2005 May; 48(5):868-77. PubMed ID: 15834550
[TBL] [Abstract][Full Text] [Related]
3. Applying some UK Prospective Diabetes Study results to Switzerland: the cost-effectiveness of intensive glycaemic control with metformin versus conventional control in overweight patients with type-2 diabetes.
Palmer AJ; Sendi PP; Spinas GA
Schweiz Med Wochenschr; 2000 Jul; 130(27-28):1034-40. PubMed ID: 10953853
[TBL] [Abstract][Full Text] [Related]
4. Cost-utility analysis of intensive blood glucose control with metformin versus usual care in overweight type 2 diabetes mellitus patients in Beijing, P.R. China.
Xie X; Vondeling H
Value Health; 2008 Mar; 11 Suppl 1():S23-32. PubMed ID: 18387063
[TBL] [Abstract][Full Text] [Related]
5. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Lancet; 1998 Sep; 352(9131):854-65. PubMed ID: 9742977
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group.
UK Prospective Diabetes Study Group
BMJ; 1998 Sep; 317(7160):720-6. PubMed ID: 9732339
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group.
Gray A; Raikou M; McGuire A; Fenn P; Stevens R; Cull C; Stratton I; Adler A; Holman R; Turner R
BMJ; 2000 May; 320(7246):1373-8. PubMed ID: 10818026
[TBL] [Abstract][Full Text] [Related]
8. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group.
Diabetes; 1995 Nov; 44(11):1249-58. PubMed ID: 7589820
[TBL] [Abstract][Full Text] [Related]
9. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
Ray JA; Boye KS; Yurgin N; Valentine WJ; Roze S; McKendrick J; Tucker DM; Foos V; Palmer AJ
Curr Med Res Opin; 2007 Mar; 23(3):609-22. PubMed ID: 17355742
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus.
Maetzel A; Ruof J; Covington M; Wolf A
Pharmacoeconomics; 2003; 21(7):501-12. PubMed ID: 12696990
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.
CDC Diabetes Cost-effectiveness Group
JAMA; 2002 May; 287(19):2542-51. PubMed ID: 12020335
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK.
Beale S; Bagust A; Shearer AT; Martin A; Hulme L
Pharmacoeconomics; 2006; 24 Suppl 1():21-34. PubMed ID: 16800160
[TBL] [Abstract][Full Text] [Related]
13. A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.
Tilden DP; Mariz S; O'Bryan-Tear G; Bottomley J; Diamantopoulos A
Pharmacoeconomics; 2007; 25(1):39-54. PubMed ID: 17192117
[TBL] [Abstract][Full Text] [Related]
14. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis.
Palmer AJ; Tucker DM
Prim Care Diabetes; 2012 Jul; 6(2):109-21. PubMed ID: 22153888
[TBL] [Abstract][Full Text] [Related]
15. Self blood glucose monitoring in type 2 diabetes. A financial impact analysis based on UK primary care.
Belsey JD; Pittard JB; Rao S; Urdahl H; Jameson K; Dixon T
Int J Clin Pract; 2009 Mar; 63(3):439-48. PubMed ID: 19222629
[TBL] [Abstract][Full Text] [Related]
16. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.
Gao L; Zhao FL; Li SC
Int J Technol Assess Health Care; 2012 Oct; 28(4):436-44. PubMed ID: 23006540
[TBL] [Abstract][Full Text] [Related]
17. Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain.
Shearer AT; Bagust A; Ampudia-Blasco FJ; Martínez-Lage Alvarez B; Pérez Escolano I; París G
Pharmacoeconomics; 2006; 24 Suppl 1():49-59. PubMed ID: 16800162
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes and not on insulin: impact of modelling assumptions on recent Canadian findings.
Tunis SL
Appl Health Econ Health Policy; 2011 Nov; 9(6):351-65. PubMed ID: 21892840
[TBL] [Abstract][Full Text] [Related]
19. An economic evaluation of atenolol vs. captopril in patients with Type 2 diabetes (UKPDS 54).
Gray A; Clarke P; Raikou M; Adler A; Stevens R; Neil A; Cull C; Stratton I; Holman R;
Diabet Med; 2001 Jun; 18(6):438-44. PubMed ID: 11472461
[TBL] [Abstract][Full Text] [Related]
20. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.
Valentine WJ; Bottomley JM; Palmer AJ; Brändle M; Foos V; Williams R; Dormandy JA; Yates J; Tan MH; Massi-Benedetti M;
Diabet Med; 2007 Sep; 24(9):982-1002. PubMed ID: 17593245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
